SNGX Stock UPDATES Soligenix Inc. (SNGX) 2.0660 08/20/2014 1

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Soligenix Inc. (SNGX) 2.0660 $SNGX

Soligenix Reports Second Quarter 2014 Financial Results, and Highlights Recent Accomplishments
PR Newswire - Mon Aug 11, 6:30AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the second quarter and six months ended June 30, 2014.

Soligenix Advances Development of a Heat Stable Rapidly Acting Anthrax Vaccine VeloThrax(TM)
PR Newswire - Thu Aug 07, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today results demonstrating the improved immunogenicity and rapid action of its anthrax vaccine, VeloThrax(TM). Previous studies had demonstrated that VeloThrax(TM) also possesses enhanced thermostability, enabling distribution without cold chain requirements.

Soligenix Receives Additional NIAID Funding to Advance Development of OrbeShield(TM) in GI ARS
PR Newswire - Fri Aug 01, 6:30AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option to advance preclinical development of OrbeShieldTM (oral beclomethasone 17,21-dipropionate or oral BDP). The 12-month option provides an additional $2.1 million to Soligenix to advance OrbeShield(TM) as a medical countermeasure (MCM) for the treatment of gastrointestinal acute radiation syndrome (GI ARS). NIAID granted an initial award of $2.1 million to Soligenix on September 18, 2013. The total contract award is valued at up to $6.4 million over three years.

Soligenix Announces Combination Vaccine for Ricin and Anthrax Achieves Simultaneous Protection
PR Newswire - Wed Jul 09, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the combination of RiVax(TM) and VeloThrax(TM) induces protective immunity to both ricin toxin and anthrax toxin exposure. RiVax(TM) is the Company's candidate vaccine for the prevention of exposure to ricin toxin using a unique antigen that is completely devoid of the toxic activity of ricin. VeloThrax(TM) is the Company's candidate vaccine that employs a derivative of recombinant protective antigen, termed Dominant Negative Inhibitor (DNI), which is a candidate for inclusion in a next generation anthrax vaccine.

Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); $5.50 Price Target
Marketwire - Wed Jun 11, 8:02AM CDT
Vista Partners announced today that it has updated coverage on Soligenix, Inc. (OTCBB: SNGX) and maintained its twelve-month price target of $5.50. Soligenix, Inc. is a New Jersey based clinical stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases.

Soligenix Reports Year-End 2013 Financial Results and Highlights Recent Accomplishments
PR Newswire - Wed Mar 26, 6:15AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the year ended December 31, 2013.

Vista Partners Initiates Coverage on Soligenix, Inc. (Ticker: SNGX); $5.50 Price Target
Marketwire - Tue Mar 18, 8:02AM CDT
Vista Partners announced today that it has initiated coverage on Soligenix, Inc. (OTCBB: SNGX) with a twelve-month price target of $5.50. Soligenix, Inc. is a New Jersey based clinical stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases. Ross Silver, Principal Analyst at Vista Partners, stated, "Soligenix has signed an exclusive worldwide collaboration deal with Intrexon Corporation ($2.9B mkt cap) (NYSE: XON) to develop a novel passive immunotherapy for Melioidosis. Melioidosis, also known as Bp, is an often deadly infectious disease caused by the bacterium, Burkholderia pseudomallei, with some symptoms similar to those of the flu and pneumonia. Melioidosis occurs in many different places around the globe, currently however it is of greatest concern in southeast-Asia and northern Australia, where public officials see it as a major threat to the health of the population." Mr. Silver continues, "The Company also has an exclusive commercial collaboration with SciClone Pharmaceuticals ($250M mkt cap) (NASDAQ: SCLN) in China for SGX942 in the treatment of oral mucositis." Mr. Silver concludes, "The Company boasts a diverse pipeline with nine prospective drug candidates. The science behind the Company's prospective therapies has been and continues to be validated by a number of significant, important and influential entities such as government organizations and major pharmaceutical companies. To date the Company has been awarded approximately $40M mainly through BARDA, NIH and FDA grants/contracts. The Company has up to approximately $34 million in active government contract and grant funding still available to support its associated research programs through 2018."

Soligenix to Present at 2014 World Vaccine Congress in Washington, DC
PR Newswire - Tue Mar 11, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that its Chief Scientific Officer, Robert N. Brey, PhD, will give a presentation on the "Development of Thermostable Subunit Vaccines" at the 2014 World Vaccine Congress - Biotech Showcase on Tuesday, March 25, 2014. The presentation will take place at 2:10 PM Eastern Daylight Time (EDT) at the Marriott Wardman Park Hotel in Washington, DC, where Dr. Brey will, in part, review the Company's achievements to date with its ThermoVax(TM) vaccine heat stabilization technology.

Soligenix Inc receives USD300,000 NIAID SBIR grant to support further evaluation of SGX943 for the treatment of melioidosis
M2 - Mon Feb 17, 6:00AM CST
Biopharmaceutical company Soligenix Inc (OTC BB:SNGX) reported on Friday the receipt of USD300,000 Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 for the treatment for melioidosis.

Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
PR Newswire - Fri Feb 14, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 as a treatment for melioidosis. The award will provide Soligenix with approximately $300,000 over one year to conduct the studies in collaboration with Tulane University.

Soligenix to Present at the 16th Annual BIO CEO & Investor Conference in New York City
PR Newswire - Wed Feb 05, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 16th Annual BIO CEO Investor Conference in New York City, on Monday, February 10, 2014 at 3:00 PM Eastern Standard Time (EST). The presentation will take place in the Conrad room at the Waldorf Astoria.

B&B Music Lessons in the Mid-Atlantic Celebrates Ninth Anniversary
PR Newswire - Tue Feb 04, 7:30AM CST
B&B Music Lessons, based in Washington, D.C., is celebrating its ninth anniversary this March. Owners Brad Clements and Bhagwan Khalsa are pleased with the progress they've made since starting the business in 2005. The school currently has 65 teachers and 370 students, mostly age five to 15.

U.S. Chamber's Global IP Center Unveils 2014 International Intellectual Property Index
PR Newswire - Tue Jan 28, 11:01PM CST
Report Sheds Light on Progress, Deficiencies in 25 Countries' IP Environments, Including Select TPP Participants

Soligenix Inc awarded USD750,000 in non-dilutive financing from New Jersey's Technology Business Tax Certificate Transfer Program
M2 - Fri Jan 17, 10:43AM CST
Biopharmaceutical company Soligenix Inc (OTC BB:SNGX) reported on Thursday that it has received about USD750,000, net of transaction costs, in non-dilutive financing via the State of New Jersey's Technology Business Tax Certificate Transfer Program.

Soligenix Receives $750,000 in Non-Dilutive Financing from New Jersey's Technology Business Tax Certificate Transfer Program
PR Newswire - Thu Jan 16, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well a developing several biodefense vaccines and therapeutics, announced today that it has recently received approximately $750,000, net of transaction costs, in non-dilutive financing via the State of New Jersey's Technology Business Tax Certificate Transfer Program (the Program).

Soligenix Announces Positive One-Year High-Temperature Stability Results with ThermoVax(TM) Vaccine Heat Stabilization Technology
PR Newswire - Wed Jan 15, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today significant steps forward in the development of ThermoVax(TM), its proprietary vaccine thermostabilization platform technology. Recent studies have demonstrated the potential for heat-sensitive vaccines formulated using this technology to withstand temperatures exceeding 40 degrees Celsius (104 degrees Fahrenheit) for up to one year. The underlying work has been conducted with the Company's proprietary ricin toxin vaccine (RiVax(TM)) as part of a continuing program to evaluate the effectiveness of protein subunit vaccines to withstand extremes of temperature and other environmental stress conditions. These studies amplify and extend former evaluations that indicated retention of potency for at least six months at temperatures as high as 40 degrees Celsius, outside the range of typical vaccine storage conditions. The research and development of ThermoVax(TM) is currently being supported by a $9.4 million National Institute of Allergy and Infectious Disease (NIAID) grant to Soligenix for biodefense vaccines to prevent ricin toxin and anthrax exposure.

Soligenix to Present at the 2014 Biotech Showcase in San Francisco
PR Newswire - Thu Jan 09, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 2014 Biotech Showcase in San Francisco, California on Tuesday, January 14, 2014 at 11:00 AM Pacific Standard Time (PST). The presentation will take place on the third floor of the Parc 55 Wyndham Hotel.

Courseload Releases Courseload Engage Learning Application for Faculty and Students
PR Newswire - Tue Jan 07, 9:00AM CST
Courseload, an institutional solution for the delivery and use of eTextbooks and digital course materials in higher education, today announced the release of Courseload Engage (Engage), its next generation application designed to enhance engagement and collaboration between students and instructors.

Soligenix Appoints Richard Straube, MD, as Chief Medical Officer
PR Newswire - Mon Jan 06, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has appointed Richard Straube, MD, as its Senior Vice President and Chief Medical Officer. Dr. Straube is a board-certified pediatrician with clinical research experience in host-response modulation. He has had a long and distinguished career of more than 35 years in both academia and industry, most notably with Centocor, Ohmeda Pharmaceuticals, INO Therapeutics, and Stealth Peptides, Inc. Dr. Straube will lead Soligenix's clinical research with primary responsibility for the execution and completion of its multiple clinical programs, including its Phase 2 study in oral mucositis and its Phase 2/3 study in pediatric Crohn's disease.

Dai Telecom and Galooli Announce Cooperation
PR Newswire - Thu Dec 19, 3:00AM CST
Dai Telecom Ltd. and Galooli Ltd. today announced cooperation in the area of remote vehicle telematics. The cooperation centers on the integration of Dai Telecom's Roadstar advanced car phone with Galooli's remote performance monitoring platform - the ZON Control. This solution enables customers to use hands free smart phone capabilities in the car along with advanced remote tracking and fleet management solution, using neither extra hardware nor installation.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

PenFed’s Toys for Tots Drive Targets Holiday Gift Gaps

Updated Category News Views 94

A missing present under a tree is not a statistic anybody ought to glide past. PenFed Credit Union has opened its annual Toys for Tots collection across Washington-region branches, taking new, unwrapped toys through December 8 at 1:00 p.m. ET. The useful detail, and frankly the one worth remembering when people default to buying the easiest shiny thing on a shelf, is...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 13

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
Humana's Medicare Audit Shock Puts Disclosure in Focus

Updated Category News Views 156

Medicare Advantage just reminded Wall Street that reimbursement plumbing can wreck a perfectly calm-looking stock in a hurry. Humana shareholders watched that lesson land hard on November 18, when reports surfaced of a proposed federal CRUSH rule aimed at fraud, waste, and improper payments in the program. The reported response in NYSE:HUM was ugly: an early account put...

Continue Reading
Africa’s Digital Leap Still Has a 64% Usage Problem

Updated Category News Views 111

A continent can be blanketed in signal and still feel digitally stranded. That is the stubborn fact sitting inside the GSMA Digital Africa Index 2026: mobile broadband reaches 92% of Africa’s population, while only 28% use mobile internet on their own devices. The 64% usage gap is not a rounding error or a tidy policy footnote. It is the whole unfinished job. From an...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 193

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 69

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 104

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
COP31 Tests Whether Climate Warnings Move Power Systems

Updated Category News Views 101

A weather alert that never reaches the control room is just expensive wallpaper. That was the useful, unsentimental thread running through a COP31 side event in Ankara on November 13: climate diplomacy is not worth much if grid operators, project owners and financiers do not change what they do when the forecast turns ugly. Implementation Means Changing Operations COP31...

Continue Reading
ACOLT Bets on Gold, Craft, and a Sci-Fi Story World

Updated Category News Views 205

A gold pendant moonlighting as a plot device is not the usual luxury pitch, and thank goodness for that. ACOLT, the Denver-based men's fine jewelry house founded by Colton Hindle, plans an international December 2026 launch of its Gold Collection alongside CHRYSON Volume 1: The Arrival, an original science-fiction comic. The actual hand-forged pieces are meant to show up...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 57

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading

Top 5 Most Recently Viewed Articles

First Advantage to Engage Investors at Wolfe FinTech Forum

Updated Category News Views 219

First Advantage to Engage Investors at Wolfe FinTech Forum ATLANTA, March 04, 2025 — First Advantage Corporation (NASDAQ: FA), renowned as a premier provider in employment background screening, identity verification, and other related solutions, is set to showcase its offerings at an upcoming pivotal event. Management of First Advantage will participate in a fireside...

Continue Reading
European Markets Open Strong: EV Collaborations Boost Sentiment

Updated Category News Views 140

European Markets Show Positive Trends European stock markets are beginning the week on a high note, reflecting a cautiously optimistic mood among investors. The overall sentiment is driven by various factors that are currently in play within the financial landscape. The DAX in Germany has risen by 0.4%, while France's CAC 40 has increased by 0.7%. In contrast, the FTSE...

Continue Reading
Southern Company Stock Reaches New Heights, Driven by Growth

Updated Category News Views 81

Southern Company Achieves Record Stock Price Southern Company (NYSE: SO) has recently celebrated a remarkable achievement with its stock price hitting a record high of $91.87. This surge marks an impressive 36.84% increase over the past year, showcasing a growing optimism among investors in the energy sector. The company has been proactive in expanding its operations...

Continue Reading
Exploring GDP Trends: Navigating Economic Uncertainties

Updated Category News Views 337

Understanding Recent GDP Trends The latest economic indicators reveal complexities that question the idea of a resilient economy. Despite these challenges, we remain optimistic for the time being. Let's take a closer look at the current situation: GDP Growth Rate Adjustments The Atlanta Fed’s GDPNow tracking model recently revised its estimated growth rate for the first...

Continue Reading
Live Nation's Ticket Sales Surge Amid Mixed Earnings Report

Updated Category News Views 347

Overview of Live Nation's Recent Performance Live Nation Entertainment, Inc. (NYSE: LYV) witnessed a notable decline in its stock price after the announcement of third-quarter earnings that did not meet market expectations. Despite the drop, the company reported impressive ticket sales and revenue growth. Financial Highlights The entertainment giant reported a substantial...

Continue Reading